Skip to main content
SpringerLink
Log in

Neue Aspekte in der Chemotherapie des fortgeschrittenen Magenkarzinoms

  • Chapter
Aktuelle Therapie des Kardiakarzinoms

Zusammenfassung

Das Magenkarzinom steht in der Todesursachenstatistik der malignen Neoplasien der Bundesrepublik Deutschland an zweiter Stelle. Jährlich werden 28 Sterbefälle auf 100000 Einwohner registriert [39].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Abbreviations

CR:

Klinische Vollremission

pCR:

Pathologisch gesicherte Vollremission

PR:

Klinische Partialremission

pPR:

Pathologisch gesicherte Partialremission

mS:

Mediane Überlebenszeit

mR:

Mediane Remissionsdauer

na:

nicht angegeben

5:

FU:5-Fluorouracil

MeCCNU:

Methyl-CCNU

Mito:

Mitomycin C

ADM:

Adriamycin

Epi-ADM:

Epiadriamycin

BAFMi:

BCNU, Adriamycin, 5-Fluorouracil, Mitomycin C

FAM:

5-Fluorouracil, Adriamycin, Mitomycin C

FAMTX:

5-Fluorouracil, Adriamycin, Methotrexat

FAB:

5-Fluorouracil, Adriamycin, BCNU

FAP:

5-Fluorouracil, Adriamycin, Cisplatin

FAMe:

5-Fluorouracil, Adriamycin, Methyl-CCNU

FEM:

5-Fluorouracil, Epiadriamycin, Mitomycin C

EAP:

Etoposid, Adriamycin, Cisplatin

Literatur

  1. Aabo K, Pedersen H, Rorth M (1985) Cisplatin in the treatment of advanced gastric carcinoma: a phase II study. Cancer Treat Rep 69: 449–450

    PubMed  CAS  Google Scholar 

  2. Aisner J, van Echo DA, Whitacre, Wiernik PH (1982) A phase I trial of continuous infusion VP16-213 (Etoposide) Cancer Chemother Pharmacol 7: 157–160

    PubMed  CAS  Google Scholar 

  3. Asakawa H, Otawa K, Watarai J (1971) High energy x-ray therapy for stomach carcinoma, second report: The evaluation of radiotherapy for the early and the inoperable stomach carcinoma. Nippon Acta Radiol 31: 505–511

    PubMed  CAS  Google Scholar 

  4. Asakawa H, Takeda T (1973) High energy x-ray therapy of gastric carcinoma. J Jpn Soc Cancer Ther 8: 362–369

    CAS  Google Scholar 

  5. Baker LH, Vaitkevicius VK, Gehan E (1976) Randomized prospektive trial comparing 5- Fluorouracil (NSC-19893) to 5-Fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer. Cancer Treat Rep 60: 733–737

    PubMed  CAS  Google Scholar 

  6. Bedikian AY, Chen TT, Khankhanian N, Heilbrun LK, McBride CM, McMurtrey MJ, Bodey GP (1984) The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol 2: 305–310

    PubMed  CAS  Google Scholar 

  7. Beer M, Cocconi G, Ceci G, Varini M, Cavalli F (1983) A phase II study of Cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 19: 717–720

    Article  PubMed  CAS  Google Scholar 

  8. Bengmark S, Jeppson B (1982) Staging of liver metastases. In: Liver metastases, Eds: Wess L, Gilberg HA, Hall GK, Boston, pp 268–274

    Google Scholar 

  9. Beretta G, Fraschini P, Labianca R, Luporini G (1982) The value of FAM polychemotherapy in advanced gastric carcinoma. Proc Amer Soc Clin Oncol 103: Abstr C-400

    Google Scholar 

  10. Beretta G, Fraschini P, Labianca R, Arnoldi E, Pancera G, Tedeschi M, Tedeschi L, Luporini G (1986) Weekly 5-Fluorouracil (F) versus combination chemotherapy for advanced gastrointestinal carcinomas. A prospective study program. Proc Amer Soc Clin Oncol 94: Abstr C-367

    Google Scholar 

  11. Biran H, Sulkes A (1984) A possible dose-response relationship in “FAM” chemotherapy for advanced gastric cancer. Proc Amer Soc Clin Oncol 132: Abstr C-515

    Google Scholar 

  12. Bleiberg H (1985) Prognostic significance of pathological staging in gastrointestinal tumors. Eur J Cancer Clin Oncol 21: 655–658

    Article  PubMed  CAS  Google Scholar 

  13. Bruckner HW, Stablein DM (1983) Sites of treatment failure: Gastrointestinal tumor study group analyses of gastric, pancreatic, colorectal trials. Cancer Treat Rep 2: 199–211

    Google Scholar 

  14. Cartei G (1985) 5-Fluorouracil, Adriamycin und Mitomycin C beim metastasierenden Magenkarzinom. In: Mitomycin’85, Eds: Nagel GA, Bach F, Bartsch HH, Aktuelle Onkologie, W. Zuckerschwerdt Verlag, Miinchen Bern Wien, pp 56–64

    Google Scholar 

  15. Cazap EL, Gisselbrecht CH, Smith FP, Estevez RA, Alvarez CA, Lagarde C, Hannols A, Ahmed S, Schein PS, Wooley PV (1986) Phase II trials of 5-FU, Doxorubicin, and Cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. Cancer Treat Rep 70: 781–783

    PubMed  CAS  Google Scholar 

  16. Childs DS, Moertel CG, Holbrook MA, Reitemeier RJ, Colby M (1986) Treatment of unresectable adenocarcinoma of the stomach with a combination of 5-Fluorouracil and radiation. Am J Roentgenol 102: 541–546

    Google Scholar 

  17. Cocconi G, DeLisi V, Di Blasio B (1982) Randomized comparison of 5—Fu alone or combined with Mitomycin and Cytarabine ( MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 66: 1263–1266

    PubMed  CAS  Google Scholar 

  18. Comis RL (1979) Mitomycin C in gastric cancer. In: Mitomycin C—Current status and new developments, Eds: Carter SK, Crooke ST, Academic Press New York, pp 129–137

    Google Scholar 

  19. Comis RL (1982) The therapy of stomach cancer. In: Principles of cancer treatment, Eds: Carter, SK, Glatstein E, Livingston RB, McGraw-Hill Book Company New York, pp 420–431

    Google Scholar 

  20. Creagan ET, O’Fallon JR, Woods JE, Ingle JN, Schutt AJ, Nichols WC (1983) Cis-diammine- dichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer. Cancer 51: 2020–2023

    Article  PubMed  CAS  Google Scholar 

  21. Cullinan SA, Moertel CG, Fleming ThR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 12: 2061–2066

    Article  Google Scholar 

  22. Cunningham D, Gilchrist NL, Forrest GJ, Soukop M, McArdle CS, Carter DC (1985) Chemotherapy in advanced gastric cancer. Cancer Treat Rep 69: 927–928

    PubMed  CAS  Google Scholar 

  23. De Lisi V, Cocconi G, Tonato M, Di Costanzo F, Leonardi F, Soldani M (1986) Randomized comparison of 5-Fu alone or combined with Carmustine, and Mitomycin (BAFMi) in the treatment of advanced gastric cancer: A phase III trial of the italian clinical research oncology group ( GOIRC ). Cancer Treat Rep 70: 481–485

    PubMed  Google Scholar 

  24. DeSimone PA, Gams R, Birch R (1986) Phase II evaluation of Mitoxantrone in advanced carcinoma of the stomach: A southeaster cancer study group trial. Cancer Treat Rep 70: 1043–1044

    PubMed  CAS  Google Scholar 

  25. Diehl JT, Herrmann RE, Cooperman AM, Hoerr SO (1983) Gastric carcinoma. A ten year review. Ann Surg 198: 9–12

    Article  PubMed  CAS  Google Scholar 

  26. Dixon WJ, Longmire WP, Holden WD (1971) Use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: Ten year follow-up. Ann Surg 173: 16–19

    Article  Google Scholar 

  27. Douglass HO Jr, Lavin PT, Goudsmit A, Klaasen DJ, Paul AR (1984) An eastern cooperative oncology group evaluation of combinations of Methyl-CCNU, Mitomycin C, Adriamycin, and 5-Fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2: 1372–1381

    PubMed  Google Scholar 

  28. Earl HM, Coombs RC, Schein PS (1984) Cytotoxic chemotherapy for cancer of the stomach. Clin Oncol 3: 351–369

    CAS  Google Scholar 

  29. Einzig A, Kelsen DP, Cheng E, Sordillo P, Heelan R, Winn R, Magil G (1985) Phase II trial of Carboplatin in patients with adenocarcinoma of the upper gastrointestinal tract. Cancer Treat Rep 69: 1453–1454

    PubMed  CAS  Google Scholar 

  30. Engstrom P, Lavin P (1983) Post-operative adjuvant therapy for gastric cancer patients. Proc Amer Soc Clin Oncol 114: Abstr C-446

    Google Scholar 

  31. Falkson G (1965) Halogenated pyrimidines as radiopotentiators in the treatment of stomach cancer. Prog Biochem Pharmacol 1: 695–700

    Google Scholar 

  32. Falkson G, Falkson HC (1969) Fluorouracil and radiotherapy in gastrointestinal cancer. Lancet 2: 1252–1259

    Article  PubMed  CAS  Google Scholar 

  33. Fielding JWL, Fagg SL, Jones BG, Ellis D, Hockey MS, Minawa A, Brookes VS, Craven JL, Mason MC, Timothy A, Waterhouse JAH (1983) An interim report of a prospective randomized controlled study of adjuvant chemotherapy in operable gastric cancer. WJ Surgery 7: 390–399

    Article  CAS  Google Scholar 

  34. Figoli F, Galligioni E, Crivellari D, Vaccher E, Lo Re G, Tumolo S, Veronesi A, Frustacia S, Canale V, Manfardini S (1986) Cisplatin (DDP) in combination with Adriamycin (A) and Fluorouracil (F) (DAF) in advanced gastric cancer - A phase II study. Proc Amer Soc Clin Oncol 95: Abstr C-369

    Google Scholar 

  35. Fornasiero A, Cartei G, Daniele O, Fosser V, Fiorentino MV (1984) FAM2 regimen in disseminated gastric cancer. Tumori 70: 77–80

    PubMed  CAS  Google Scholar 

  36. Gastrointestinal Tumor Study Group (1982) A combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 49: 1771–1777

    Article  Google Scholar 

  37. Gastrointestinal Tumor Study Group (1982) Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49: 1116–1122

    Article  Google Scholar 

  38. Gelber RD, Zelen M (1985) Planning and reporting of clinical trials. In: Medical oncology, Eds: Calabresi PC, Schein PC, Rosenberg S, Mcmillan Publishing Company, New York, pp 406–425

    Google Scholar 

  39. Gesundheitswesen, Fachserie 12 (1984) Todesursachen 1983. Eds: Statistisches Bundesamt Wiesbaden, W Kohlhammer Verlag, Stuttgart, pp 12–19

    Google Scholar 

  40. Greco FA, Johnson DH, Hände RK, Porter LL, Hainsworth JD, Wolff SN (1985) High-dose Etoposide (VP-16) in small-cell lung cancer. Sem Oncol 12 (Suppl 2): 42–44

    CAS  Google Scholar 

  41. Gunderson LL, Hoskins B, Cohen AM, Kaufman S, Wood WC, Carey RW (1983) Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys 9: 965–975

    Article  PubMed  CAS  Google Scholar 

  42. Haas C, Oishi N, McDonald B, Coltman C, O’Bryan R (1983) Southwest oncology group phase II–III gastric cancer study: 5-Fluorouracil, Adriamycin, and Mitomycin C ± Vincristine (FAM vs V-FAM) compared to Chlorozotocin (CZT), M-AMSA, and Dihydroxyanthracenedione ( DHAD) with unimpressive differences. Proc Amer Soc Clin Oncol 2: 122

    Google Scholar 

  43. Haas L, Vaitkevicius V, Bukowski R, Moore D, Mansfield K (1980) Southwest oncology group (SWOG) pilot study of radiotherapy (R)+5-Fluorouracil (F)+Adriamycin+Mitomycin C (M) in patients with minimal residual gastric cancer. Proc Amer Soc Clin Oncol 342: Abstr C-439

    Google Scholar 

  44. Haim N, Cohen Y, Honigman J, Robinson E (1982) Treatment of advanced gastric carcinoma with 5-Fluorouracil, Adriamycin, and Mitomycin C ( FAM ). Cancer Chemother Pharmacol 8: 277–280

    Article  PubMed  CAS  Google Scholar 

  45. Haim N, Epelbaum R, Cohen Y, Robinson E (1984) Further studies in the treatment of advanced gastric cancer by 5-Fluorouracil, Adriamycin ( Doxorubicin), and Mitomycin C (modified FAM ). Cancer 54: 1999–2002

    Article  PubMed  CAS  Google Scholar 

  46. Herrmann R, Fritze D, Queißer W, Flechtner H, Ho AD, Schlag P, König H (1984) Chemotherapie des Magenkarzinoms., Dtsch med Wschr 109: 1704

    Google Scholar 

  47. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Kheen RJ (1983) Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. Cancer 52: 1105–1110

    Article  PubMed  CAS  Google Scholar 

  48. Kantarjian H, Ajani JA, Karlin DA (1985) Cis-Diamminodichloroplatinum ( II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 42: 69–71

    Article  PubMed  CAS  Google Scholar 

  49. Kelsen DP, Magill G, Cheng E, Coonley C, Yagoda A (1982) Phase II trial of Etoposide (VP16) in the treatment of upper gastrointestinal malignancies. Proc Amer Soc Clin Onco 96: Abstr C- 371

    Google Scholar 

  50. Kim NK (1984) Chemotherapy of advanced gastric carcinoma with 5-Fluorouracil, Adriamycin, Mitomycin (FAM), and 5-Fluorouracil, Adriamycin, Cisplatin (FAP) combinations: Experience in Korea. In: Adriamycin, its expanding role in cancer treatment, Eds: Ogawa M, Muggia FM, Rozenczweig M, Excerpta Medica, Amsterdam, pp 137–145

    Google Scholar 

  51. Klein HO, Wickramanyake PD, Farrkh G-R (1986) 5-Fluorouracil (5-Fu), Adriamycin (ADM), and Methotrexate (MTX)-A combination protocol (FAMTX) for treatment of metastasized stomach cancer. Proc Amer Soc Clin Oncol 84: Abstr C-325

    Google Scholar 

  52. Kodama Y, Sugimachi K, Soejima K (1981) Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 5: 241–248

    Article  PubMed  CAS  Google Scholar 

  53. Kolaric K, Petrebica V, Stanovnik M (1986) Controlled phase III clinical study of 4-Epi- Doxorubicin + 5-Fluorouracil versus 5-Fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology 43: 73–77

    Article  PubMed  CAS  Google Scholar 

  54. Kovach JS, Moertel CG, Schutt AJ (1974) A controlled trial of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-Fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 33: 563–567

    Article  PubMed  CAS  Google Scholar 

  55. Koyama Y, Kimura T (1978) Controlled clinical trials of chemotherapy as an adjuvant to surgery in gastric carcinoma. Proc 2nd Int, Cancer Congr Buenos Aires, pp 1–21

    Google Scholar 

  56. Lacave AJ, Wils H, Bleiberg E, Diaz Rubio M, Clavel A, Planting O, Duez N (1986) Advanced and chemotherapy-resistant gastric cancer (GC): Benefit of additional MeCCNU (Me) and evaluation of CDDP (P). E.O.R.T.C. Symposium on Gastrointestinal Tract Cancer, Heidelberg, May 29–30

    Google Scholar 

  57. Lacave AJ, Wils J, Diaz-Rubio E, Clavel M, Planting A, Bleiberg H, Duez N, Dalesio O (1985) Phase II study of Cisplatin (DDP) in chemotherapy resistant carcinoma of the stomach. Cancer Chemother Pharmacol 14 (Suppl): 39–42

    Google Scholar 

  58. Lagunova IG, Cybulskij BA, Minerva OD, Sakaja IS (1978) Aufeinander folgende Strahlentherapie mit einem 25-meV Betatron und Chemotherapie mit Fluorouracil zur Behandlung von Kranken mit fortgeschrittenem Krebs des oberen Magenabschnittes. Radiobiol Radiother 13: 307

    Google Scholar 

  59. Lavin PT, Bruckner HW, Plaxe SC (1982) Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 50: 2016–2023

    Article  PubMed  CAS  Google Scholar 

  60. Leichmann L, MacDonald B, Dindogru A, Samson M (1982) Platinum: A clinical active drug in advanced adenocarcinoma of the stomach. Proc Amer Assoc Cancer Res 110: Abstr 430

    Google Scholar 

  61. Levi JA, Dalley DN, Aroney RS (1979) Improved combination chemotherapy in advanced gastric cancer. Brit Med J 2: 1471–1473

    Article  PubMed  CAS  Google Scholar 

  62. Levi JA, Fox RM, Tattersall MH, Woods RL, Thomson D, Gill G (1986) Analysis of a prospective randomized comparison of Doxorubicin versus 5-Fluorouracil, Doxorubicin, and BCNU in advanced gastric cancer: Implications for future studies. J Clin Oncol 4: 1348–1355

    PubMed  CAS  Google Scholar 

  63. Lopez M, Di Lauro L, Papaldo P, Conti EMS (1986) Treatment of advanced measurable gastric carcinoma with 5-Fluorouracil, Adriamycin, and BCNU. Oncology 43: 288–291

    Article  PubMed  CAS  Google Scholar 

  64. Lopez M, Perno CF, Di Lauro L, Papaldo P (1984) 5-Fluorouracil, Adriamycin, BCNU (FAB) combination chemotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 12: 194–197

    Article  PubMed  CAS  Google Scholar 

  65. MacDonald JS, Gunderson LL, Cohn I Jr (1985) Cancer of the stomach. In: Cancer, principles & practice of oncology, Eds: DeVita VT, Hellman S, Rosenberg SA, J. B. Lippincott, Philadelphia, pp 534–552

    Google Scholar 

  66. MacDonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C (1980) 5-Fluorouracil, Doxorubicin, and Mitomycin ( FAM) combination-chemotherapy for advanced gastric cancer. Ann Int Med 93: 533–536

    PubMed  CAS  Google Scholar 

  67. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214

    Article  PubMed  CAS  Google Scholar 

  68. Moertel CG (1973) Therapy of advanced gastrointestinal cancer with the nitosoureas. Cancer Chemother Rep 4: 27–34

    CAS  Google Scholar 

  69. Moertel CG, Fleming T, O’Connell M, Schutt M, Rubin J (1984) A phase II trial of combined intensive course 5-Fu, Adriamycin and Cis-Platinum in advanced gastric and pancreatic carcinoma. Proc Amer Soc Clin Oncol 137: Abstr C-535

    Google Scholar 

  70. Moertel CG, Lavin PT (1979) Phase II–III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1863–1869

    PubMed  CAS  Google Scholar 

  71. Moertel CG, Mittelman JA, Bakermeier RF, Engstrom P, Hanley J (1976) Sequential and combination chemotherapy of advanced gastric cancer. Cancer 38: 678–681

    Article  PubMed  CAS  Google Scholar 

  72. Moertel CG, Rubin J, O’Connell MJ, Schutt AJ, Wieand HS (1986) A phase II study of combined 5-Fluorouracil, Doxorubicin, and Cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053–1057

    PubMed  CAS  Google Scholar 

  73. Muro H, Romero Acuna L, Castagnari A, Blajman C, Schmilovich A, Hidalgo A, Fiori H, Bader M, Marantz A (1986) Sequentiell Methotrexate, 5-Fluorouracil (high dose), and Doxorubicin for advanced gastric cancer. Cancer Treat Rep 70: 1333–1334

    PubMed  CAS  Google Scholar 

  74. Nekajima T, Harashima S, Hirata M (1978) Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytol 22: 225–229

    Google Scholar 

  75. O’Connell MJ (1985) Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 3: 1032–1039

    PubMed  Google Scholar 

  76. Oshima K, Yamada T, Nonaka T, Aoyama M, Hirose H, Adachi N, Kobayachi S, Udo K (1982) Treatment of advanced G.I. cancer patients with 5-Fu, Adriamycin, and Mitomycin C (FAM). Proc 13th Intern Cancer Congress Seattle 8–15th Sept, 665, Abstr 3977

    Google Scholar 

  77. Pannettiere FJ, Haas Ch, McDonald B, Costanzi JJ, Talley RW, Athens J, Oishi N, Heilbrun LK, Chen TT (1984) Drug combinations in the treatment of gastric adenocarcinoma: A randomized southwest oncology group study. J Clin Oncol 2: 420–424

    Google Scholar 

  78. Perry MC, Green MR, Mick R, Schein P (1986) Cisplatin in patients with gastric cancer: A cancer and leukemia group B phase II study. Cancer Treat Rep 70: 415–416

    PubMed  CAS  Google Scholar 

  79. Preusser P, Achterrath W, Niederle N, Seeber S (1985) Cisplatin. Arzneimitteltherapie 2: 50–56

    Google Scholar 

  80. Preusser P, Wilke H, Neuhaus B, Achterrath W (1986) Pilotstudie mit der Kombination Etoposid, Adriamycin, Cisplatin beim fortgeschrittenen, inoperablen Magenkarzinom. Tumor Diagnostik & Therapie 4: 142–144

    Google Scholar 

  81. Preusser P, Wilke H, Achterrath W,Neuhaus B, Hiddemann W, Urbanitz D, van de Loo J (1986) Etoposide (E)/Adriamycin (A)/Cisplatin (P) = EAP in advanced gastric cancer: A pilot and phase II study. 14th International Cancer Congress, Budapest, Hungary, August 21–27,209, Abstr 796

    Google Scholar 

  82. Queißer W, Flechtner H, Heim ME, Henß H, Arnold H, Fritze D, Herrmann R, Fritsch H, Penzkofer F, Trux FA, Kabelitz K, Edler L (1986) 5-Fluorouracil, 4-Epidoxorubicin, and Mitomycin C (FEM) for advanced gastric carcinoma, a phase II trial. J Cancer Res Clin Oncol 111 (Suppl): 85

    Google Scholar 

  83. Robinson E, Haim N, Epelbaum R, Cohen Y (1985) Phase II trials in the treatment of advanced gastric Cancer I - 5-Fluorouracil, Adriamycin and Mitomycin (FAM), II - Cisplatin, Adriamycin and 5-Fluorouracil ( DAF ). Proc Amer Soc Clin Oncol 77

    Google Scholar 

  84. Rougier P, Droz JP, Amiel JL, Ruffier P, Theodore C, Kac J, Chavy A (1985) Gastric carcinoma: A phase II trial of chemotherapy with association 5-Fluorouracil (5 FU), Adriamycin (ADR) and Cisplatin (DDP) (FAP Protocol) in metastasized or inoperable patients. Preliminary results. Cancer Chemother Pharmacol 14 (Suppl): 54–59

    Google Scholar 

  85. Schein PS, MacDonald JS, Hoth D, Wooley PV (1978) Mitomycin C: Experience in the United States, with emphasis on gastric cancer. Cancer Chemother Pharmacol 1: 73–75

    Article  PubMed  CAS  Google Scholar 

  86. Schein PS, Smith FP, Dritschillo A, Stablein DM, Ahlgren JD (1983) Phase I-II trial of combined modality FAM plus split-course radiation (FAM-RT-FAM) for locally advanced gastric and pancreatic cancer: A midatlantic oncology program study. Proc Amer Soc Clin Oncol 126

    Google Scholar 

  87. Scher I, Geller NL, Muggia FM, Rozencweig M (1987) Clinical evaluation of anticancer treatments: Phase II clinical trials. In: Clinical evaluation of antitumor therapy, Eds: Muggia FM, Rozencweig M, Martinus Nijhoff Publishing, Boston, pp 175–197

    Chapter  Google Scholar 

  88. Scherdin G, Garbrecht M, Müllerleile U, Hossfeld DK (1986) Polychemotherapy with Methotrexate in medium dosage rang, 5-Fluorouracil and Adriamycin in advanced gastric carcinoma. J Cancer Res Clin Oncol 111 (Suppl): 58

    Google Scholar 

  89. Schnitzler G, Queißer W, Heim ME, König H, Katz R, Fritze D, Herrmann R, Arnold H, Henss H, Trux FA, Bloch R, Keymlining M, Wolkewitz KD, Fritsch H, Hanisch I, Brumen L, Edler L (1986) Phase III study of 5-Fu and Carmustine versus 5-Fu, Carmustine, and Doxorubicin in advanced gastric cancer. Cancer Treat Rep 70: 477–479

    PubMed  CAS  Google Scholar 

  90. Seeber S, Osieka R, Schmidt CG, Achterrath W, Crooke ST (1982) In vivo resistance towards Anthracylines, Etoposide, and Cis-diaminedichloroplatinum ( II ). Cancer Res 67: 4719–4725

    Google Scholar 

  91. Serlin O, Wolkoff JS, Amadeo JM, Keehn RJ (1969) Use of 5-Fluorodeoxyuricine ( FudR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 24: 223–227

    Article  PubMed  CAS  Google Scholar 

  92. Simon RS (1985) Design and conduct of clinical trials. In: Cancer, principles & practice of oncology, Eds: DeVita VT, Hellman S, Rosenberg SA, J.B. Lippincott, Philadelphia, pp 329–350

    Google Scholar 

  93. The Gastrointestinal Tumor Study Group (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1871–1876

    Google Scholar 

  94. The Gastrointestinal Tumor Study Group (1984) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53: 13–17

    Article  Google Scholar 

  95. UICC: TNM-Atlas (1985) Eds: Spiesse B, Hermanek P, Scheibe O, Wagner G, Springer Verlag, Berlin, pp 90–98

    Google Scholar 

  96. Wagener DJTh, Yap SH, Wobbes T, Burghouts JTM, van Dam FE, Hillen HFP, Hoogendoorn GJ, Scheerder H, van der Vegt SGL (1985) Phase II trial of 5-Fluorouracil, Adriamycin, and Cisplatin ( FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15: 86–87

    Article  PubMed  CAS  Google Scholar 

  97. Walder S, Green M, Muggia F (1985) The role of anthracyclines in the treatment of gastric cancer. Cancer Treat Rev 12: 105–132

    Article  Google Scholar 

  98. Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, Splinter Z, Duez N (1986) An EORTC gastrointestinal group evaluation of the combination of sequential Methotrexate and 5- Fluorouracil, combined with Adriamycin in advanced measurable gastric cancer. J Clin Oncol 4: 1799–1803

    PubMed  CAS  Google Scholar 

  99. Wooley P, Smith F, Estevez R, Gisselbrecht C, Alvarez C, Boiron M, Machado C, Lagarde C, Schein PS (1981) A phase II trial of 5-Fu, Adriamycin and Cisplatin ( FAP) in advanced gastric cancer. Proc Amer Soc Clin Oncol 455

    Google Scholar 

Download references

Authors
  1. P. Preusser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Achterrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H.-J Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Heinicke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Bünte
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chirurgische Klinik und Poliklinik, der Universität Münster, Jungeblodtplatz 1, 4400, Münster, Germany

    P. Langhans  & H. Bünte  & 

  2. Chirurgische Klinik, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 2000, Hamburg 20, Germany

    H. W. Schreiber

  3. Chirurgische Klinik und Poliklinik Universitätsklinikum Steglitz, der Freien Universität Berlin, Hindenburgdamm 30, 1000, Berlin 45, Germany

    R. Häring

  4. Klinik für Chirurgie, der Wilhelm-Pieck-Universität Rostock, Leninallee 35, DDR-2500, Rostock, Germany

    R. Reding

  5. Chirurgische Klinik und Poliklinik rechts der Isar, Technischen Universität München, Ismaninger Straße 22, 8000, München 80, Germany

    J. R. Siewert

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Preusser, P. et al. (1988). Neue Aspekte in der Chemotherapie des fortgeschrittenen Magenkarzinoms. In: Langhans, P., Schreiber, H.W., Häring, R., Reding, R., Siewert, J.R., Bünte, H. (eds) Aktuelle Therapie des Kardiakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73427-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73427-4_23

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73428-1

  • Online ISBN: 978-3-642-73427-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation